Drug management risk assessment method and device

Abstract

The invention provides a drug management risk assessment method and device. The method comprises the steps of obtaining an updated drug management risk point and a risk index of the drug management risk point; obtaining an index score of the drug management risk point for each risk index; based on the index score, determining a risk area where the index score is located from a preset drug risk matrix; calculating a risk score of the drug management risk point based on the index weight of the risk index and the index score; and sorting all the drug management risk points based on the risk areas and the risk scores to obtain a first rectification sequence of the drug management risk points. According to the invention, the evaluation efficiency and accuracy of the drug management risk can be improved, and the risk point in each link of drug management can be identified and improved conveniently.

Description

Technical Field

[0001] This application relates to the technical field of drug management, and in particular to a method and apparatus for drug management risk assessment. Background Technology

[0002] Drug therapy is a primary means of treating patients in medical institutions. Risks at every stage of drug administration, from storage to use, directly impact the success of treatment and medication safety. According to the 2021 National Clinical Safe Medication Monitoring Network Annual Report, 72.16% of medication errors occurred during the doctor's prescription stage, 20.52% during drug procurement, storage, and dispensing, and 2.80% during the nurse's administration. Administrative management and information-related issues also contribute to medication errors. These data indicate that managing drug risks in medical institutions is a systematic project that requires the use of professional drug risk assessment techniques to help shift the focus to prevention.

[0003] Currently, medical institutions often use quality management tools such as brainstorming, FMEA (HFMEA), and PDCA for drug risk assessment. However, these tools only reveal one aspect of the risk system and are not comprehensive enough. Each assessment requires the formation of an assessment team, which is time-consuming, labor-intensive, and difficult, hindering practical implementation. Therefore, there is an urgent need to develop a simple and rapid drug management risk assessment method for medical institutions to facilitate the identification and improvement of high-risk points in all aspects of drug management. Summary of the Invention

[0004] To improve the efficiency and accuracy of drug management risk assessment and facilitate the identification and improvement of risk points in various aspects of drug management, this application provides a drug management risk assessment method and apparatus.

[0005] Firstly, this application provides a method for assessing drug administration risks, including:

[0006] Obtain updated drug management risk points and risk indicators for those drug management risk points;

[0007] Obtain the indicator score for each of the aforementioned drug management risk indicators;

[0008] Based on the index score, the risk zone in which the index score is located is determined from the preset drug risk matrix;

[0009] The risk score of the drug management risk point is calculated based on the indicator weight and the indicator score of the risk indicator.

[0010] Based on the risk areas and risk scores, all drug management risk points are sorted to obtain the first rectification sequence of drug management risk points.

[0011] Preferably, in response to the risk indicators including a first indicator, a second indicator, and a third indicator, the method for constructing the drug risk matrix includes:

[0012] A first drug risk matrix is ​​constructed based on the first indicator, the score of the first indicator, the second indicator, and the score of the second indicator;

[0013] A second drug risk matrix is ​​constructed based on the first indicator, the score of the first indicator, the third indicator, and the score of the third indicator;

[0014] A third drug risk matrix is ​​constructed based on the second indicator, the score of the second indicator, the third indicator, and the score of the third indicator.

[0015] Preferably, the method for determining the risk area includes:

[0016] Based on the ALARP principle, the first drug risk matrix, the second drug risk matrix and the third drug risk matrix are divided into risk regions, which include high-risk areas, medium-risk areas and low-risk areas.

[0017] Obtain the first high-risk area in the first drug risk matrix, the second high-risk area in the second drug risk matrix, and the third high-risk area in the third drug risk matrix. Then merge the first high-risk area, the second high-risk area, and the third high-risk area to obtain the merged high-risk area.

[0018] Obtain the first medium-risk area in the first drug risk matrix, the second medium-risk area in the second drug risk matrix, and the third medium-risk area in the third drug risk matrix. Then merge the first medium-risk area, the second medium-risk area, and the third medium-risk area to obtain the merged medium-risk area.

[0019] Obtain the first low-risk area in the first drug risk matrix, the second low-risk area in the second drug risk matrix, and the third low-risk area in the third drug risk matrix. Then merge the first low-risk area, the second low-risk area, and the third low-risk area to obtain the merged low-risk area.

[0020] Preferably, the method for obtaining the indicator weights of the risk indicators includes:

[0021] A hierarchical model is constructed, which includes an objective layer and a criterion layer. The objective layer is used to calculate the weights of the indicators, and the criterion layer includes the risk indicators.

[0022] Based on the risk indicators in the criterion layer, a judgment matrix is ​​constructed;

[0023] Obtain the maximum eigenvalue of the judgment matrix and the maximum eigenvector corresponding to the maximum eigenvalue;

[0024] The weight of each risk indicator is determined based on the maximum eigenvector.

[0025] Preferably, after calculating the risk score of the high-risk point in drug management based on the indicator weights and scores of the risk indicators, the method further includes:

[0026] In response to the fact that any two or more of the drug management risk points have the same risk score, the Borda number of the drug management risk points with the same risk score is calculated based on the Borda ordinal value method.

[0027] Based on the Borda number, the drug management risk points with the same risk score are ranked to obtain the second rectification sequence of the drug management risk points;

[0028] Based on the first rectification sequence and the second rectification sequence, the target rectification sequence for the drug management risk points is determined.

[0029] Preferably, the method for obtaining drug management risk points includes:

[0030] Obtain historical medication error cases and identify initial drug management risk points from these cases;

[0031] The initial drug management risk points are preprocessed to determine the drug management risk points.

[0032] Secondly, this application provides a drug administration risk assessment device, comprising:

[0033] The basic data acquisition module is used to acquire drug management risk points and risk indicators of the drug management risk points;

[0034] The indicator score calculation module is used to obtain the indicator score of each of the drug management risk points for each risk indicator;

[0035] The risk area division module is used to determine the risk area where the indicator score is located from a preset drug risk matrix based on the indicator score.

[0036] The risk score calculation module is used to calculate the risk score of the drug management risk point based on the indicator weight and the indicator score of the risk indicator.

[0037] The rectification sequence acquisition module is used to sort all the drug management risk points based on the risk area and the risk score, and obtain the first rectification sequence of the drug management risk points.

[0038] Preferably, the rectification sequence acquisition module is further configured to, in response to any two or more drug management risk points having the same risk score, calculate the Borda number of the drug management risk points with the same risk score based on the Borda ordinal value method;

[0039] The rectification sequence acquisition module is also used to sort the drug management risk points with the same risk score based on the Borda number, and obtain the second rectification sequence of the drug management risk points.

[0040] The rectification sequence acquisition module is also used to determine the target rectification sequence of the drug management risk point based on the first rectification sequence and the second rectification sequence.

[0041] Thirdly, this application provides an electronic device, including: a processor, and a memory communicatively connected to the processor;

[0042] The memory stores computer-executed instructions;

[0043] The processor executes computer execution instructions stored in the memory to implement the method described above.

[0044] A fourth aspect of this application provides a computer-readable storage medium storing computer-executable instructions that, when executed by a processor, are used to implement the method described above.

[0045] This application provides a method and apparatus for assessing drug management risks. By acquiring the updated index scores of drug management risk points on each risk indicator, the risk level of the drug management risk point can be determined by judging the risk area in which the index score of the drug management risk point is located within the drug risk area. This allows for the rapid classification of drug management risk points into high-risk, medium-risk, and low-risk categories. Further calculation of the risk scores of drug management risk points yields the first rectification sequence for drug management risk points in different risk areas within the high-risk, medium-risk, and low-risk zones. This facilitates the identification and improvement of risk points in various aspects of drug management, thereby improving the efficiency and accuracy of drug management risk assessment.

[0046] Additional aspects and advantages of this application will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of this application. Attached Figure Description

[0047] The above and / or additional aspects and advantages of this application will become apparent and readily understood from the following description of the embodiments taken in conjunction with the accompanying drawings, wherein:

[0048] Figure 1This is a flowchart illustrating a drug management risk assessment method in an embodiment of this application.

[0049] Figure 2 This is a flowchart illustrating steps S201-S204 of a drug management risk assessment method according to an embodiment of this application.

[0050] Figure 3 This is a flowchart illustrating steps S301-S304 of a drug management risk assessment method according to an embodiment of this application.

[0051] Figure 4 This is a flowchart illustrating steps S401-S403 of a drug management risk assessment method according to an embodiment of this application.

[0052] Figure 5 This is a schematic diagram of a drug management risk assessment device according to an embodiment of this application.

[0053] Explanation of reference numerals in the attached figures:

[0054] 1. Basic data acquisition module; 2. Indicator score calculation module; 3. Risk area division module; 4. Risk score calculation module; 5. Rectification sequence acquisition module. Detailed Implementation

[0055] The embodiments of this application are described in detail below. Examples of these embodiments are shown in the accompanying drawings, wherein the same or similar reference numerals denote the same or similar elements or elements having the same or similar functions throughout. The embodiments described below with reference to the accompanying drawings are exemplary and intended to explain this application, and should not be construed as limiting this application.

[0056] The following description, with reference to the accompanying drawings, illustrates a method and apparatus for assessing drug management risks according to embodiments of this application.

[0057] This application provides a method for assessing drug management risks, referring to... Figure 1 This includes the following steps:

[0058] S101. Obtain drug management risk points and risk indicators for drug management risk points;

[0059] S102. Obtain the indicator score for each risk indicator for drug management risk points;

[0060] S103. Based on the indicator scores, determine the risk area where the indicator scores are located from the preset drug risk matrix;

[0061] S104. Calculate the risk score of drug management risk points based on the indicator weights and indicator scores of risk indicators;

[0062] S105. Based on the risk area and risk score, sort all drug management risk points to obtain the first rectification sequence of drug management risk points.

[0063] Step S101: Obtain drug management risk points. In this embodiment, historical medication error cases are obtained, and the medication error links in these cases are extracted. The nodes in these error links are then used as the initial drug management risk points in this embodiment. These historical medication error cases can be obtained through the hospital's network data.

[0064] Simultaneously, initial drug management risk points can be identified by screening relevant literature and research on medication errors. Specifically, a comprehensive search can be conducted using a search platform with keywords as search information. Keywords include "medication error," "drug side effects," and "medical malpractice." After retrieving relevant research literature, initial drug management risk points can be determined based on historical medication error cases recorded in the literature.

[0065] Of course, risk points in the drug management process can also be identified through experts in relevant fields, such as the Delphi expert consultation method, which can also yield initial drug management risk points. In this embodiment, drug management risk points are determined through historical medication error cases, which can better reflect the actual situation of drug management in medical institutions and ensure the reliability of data such as drug management risk points.

[0066] Specifically, because medical institutions use different management methods at different times, it is necessary to update and statistically analyze drug management risk points regularly and conduct drug management risk assessments. Therefore, the drug management risk assessment method in this embodiment can be used long-term and improves the timeliness of drug management risk assessment.

[0067] After obtaining the initial drug management risk points, the initial drug management risk points are preprocessed, such as removing duplicate data and irrelevant data, to obtain the drug management risk points.

[0068] The drug management risk points in this embodiment are identified from different circulation stages within the medical institution, including drug procurement, storage, prescription / medical order issuance, prescription / medical order review, drug dispensing, drug preparation, drug use, and pharmaceutical management. Examples of the drug management risk points identified in this embodiment include:

[0069] Regarding the drug procurement process, drug management risks may include: 1. Timeliness of drug procurement; 2. Timeliness of clinical drug use; 3. Whether procurement is in violation of regulations; 4. Completeness of drug information; 5. Whether drug information is erroneous; 6. Minimizing the number of drugs with similar therapeutic effects in the hospital's essential drug supply list; 7. When purchasing drugs, fully assessing the potential medication error and adverse reaction risks of drugs to be included in the hospital's drug list; 8. Timely adding drugs to be purchased to the hospital information system's drug dictionary database; 9. The hospital information system should use a unified and standardized method to represent drug names, specifications, routes of administration, etc., and continuously improve the representation of the above information through certain quality management measures; 10. Timely cessation of clinical use when a drug is in short supply; 11. Timely notification of clinical departments when there are drug warnings, etc.

[0070] Regarding drug storage, drug management risks may include: 1. Drug storage conditions; 2. Drug expiration date; 3. Management of specially controlled drugs; 4. Qualifications of drug management personnel; 5. Drug packaging; 6. Management of easily confused drugs; 7. Drug labeling; 8. The packaging and labeling of all large-volume non-intravenous infusion fluids (sterile water for injection, physiological sodium chloride solution, flushing solution, organ preservation solution, etc.) should be clearly distinguishable from intravenous infusions, and they should be differentiated by being stored in different areas; 9. Common chemicals used for disinfection, cleaning, or formulation preparation should be stored separately from drugs and have clear and unambiguous labels that must indicate the name, content, and other information. After opening, the open and expiration dates should also be marked; 10. Chemicals that may be confused with drugs should not be stored in drug storage areas; 11. Ensure that drug storage areas are adequately lit (light intensity not less than 200 Lx) so that staff can clearly read labels and other important drug information; 12. Have sufficient space, equipment, and drugs, etc.

[0071] Regarding the prescription / medical order issuance process, potential risks in drug management include: 1. Doctors can easily obtain inpatient laboratory test results electronically from their workplace; 2. When prescribing medications that require dosage adjustments based on laboratory test results, the computer-based medical order entry system can automatically display the relevant laboratory indicators for recent inpatients and outpatients; 3. Patient basic information, medical records, and medication treatment records can be continuously stored in the hospital information system for more than 5 years and can be provided to medical staff when patients visit or are admitted again; 4. Information is shared between the hospital's outpatient and inpatient information systems. 5. Regardless of whether a patient visits the outpatient or inpatient department, medical staff can easily access comprehensive past medical information; 6. Emphasis is placed on timely collection of patient allergy information, ensuring that allergy information entered into the information system has been verified by medical staff, is accurate, and that allergen names are standardized and properly coded, so that the computer-aided clinical decision support system can correctly screen allergy information; 7. The hospital information system can automatically screen for medications that may cause allergies based on the patient allergy information recorded in the system, and issue warnings when medical staff enter prescriptions, with the warnings only being lifted after medical staff enter a reasonable explanation into the information system; 8. The patient's allergy information is clearly displayed in a designated location on all patient-related pages in the hospital information system's patient medication records, prescription entry system, and intelligent medicine cabinet operating system; 9. Prescriptions can only be entered after the patient's weight has been entered into the hospital information system.

[0072] Regarding the prescription / medical order review process, potential risks in drug management include: 1. Pharmacists have access to detailed patient prescriptions or medical orders; 2. Pharmacists collect information on patients' comorbidities and chronic diseases (such as hypertension, diabetes, liver and kidney dysfunction, pregnancy, and breastfeeding). Pharmacists can obtain this information through the pharmacy information system for reference; 3. Medical institutions regularly review the charts, guidelines, and drug instructions they use, promptly updating and discontinuing the use of outdated documents; 4. All outpatient and emergency prescriptions must be reviewed by a pharmacist; 5. All medical orders must be reviewed by a pharmacist, etc.

[0073] Regarding the medication dispensing process, potential risks in medication management include: 1. Pharmacists providing rational drug use consultations and patient medication education in outpatient and emergency departments; 2. The dosage and drug name on the label of medications dispensed by the pharmacy department must match the information in the medication management record; 3. High-alert medications dispensed by the pharmacy department should be distributed to wards separately, or individually packaged in standardized bags or boxes before being distributed to wards along with other medications to avoid mixing; 4. All oral solid medications distributed to wards should be labeled and be single-dose medications that nurses can administer directly; 5. If the hospital uses intelligent medicine cabinets, fully automated dispensing machines, tablet repackaging machines, or barcode technology (for medication management), their usage should be regularly monitored. 6. Analyze and summarize the occurrence of malfunctions and related errors, and make corresponding improvements to reduce the frequency of unsuitable operations; 7. All staff operating equipment related to drug dispensing should receive training on the equipment they operate and pass an assessment and certification to ensure they are capable of operating the equipment before officially starting work; 8. Ensure sufficient lighting in the pharmacy work area (light intensity not less than 200 Lx) so that staff can clearly read labels and other important drug information; 9. Except in emergencies, if staff work in shifts, at least 10 hours of rest should be guaranteed between shifts; 10. Except in emergencies, ensure that staff have at least one 15-minute break and a 30-minute meal break during every 8-hour workday.

[0074] For the drug preparation process, drug risk management points may include: 1. Ensuring timely medication use in wards; 2. Correctness of drug preparation; 3. Correctness of drug dosage; 4. Correctness of drug solvent; 5. Standardization of preparation procedures; 6. Finished product qualification rate; 7. Preparation environment; 8. Except in emergencies (first aid or when readily available intravenous infusions are unavailable), intravenous infusions should not be prepared in wards; 9. Chemicals that may be confused with drugs should not be stored in the preparation center (or preparation area); 10. All personnel operating equipment related to drug preparation, etc. Before officially starting work, all staff should receive training related to the equipment they operate and pass an assessment to ensure they are qualified to operate the equipment; 11. Ensure adequate lighting in the work area (light intensity not less than 200 Lx) so that staff can clearly read labels and other important drug information; 12. Except in emergencies, if staff work in shifts, at least 10 hours of rest should be guaranteed between shifts; 13. Except in emergencies, ensure that staff have at least one 15-minute break and a 30-minute meal break during every 8-hour workday.

[0075] For medication administration, risk management points may include: 1. Nurses having convenient access to inpatient laboratory test results electronically at their workplace; 2. For patients receiving moderate to deep sedation, patient-controlled analgesia, epidural anesthesia, or other injectable opioid pain treatment, monitoring and assessing patient alertness and vital signs (respiratory rate and respiratory quality) should be used to avoid oversedation; 3. For patients receiving patient-controlled analgesia or other injectable opioid analgesia, if they also have the following risk factors, such as obesity, underweight, sleep apnea, concurrent intravenous infusion of drugs that interact with opioids, asthma attacks, and nurse-controlled analgesia, further monitoring methods than blood oxygen saturation, such as end-tidal carbon dioxide monitoring or apnea alarms, are required. The above measures should also be taken when using nurse-controlled analgesia; 3. Use machine-readable coding technology (such as barcodes) to identify patients during medication administration; or select two pieces of information from the hospital information system medication management record (or paper version) or original prescription to verify the information on the patient's wristband and / or the patient's identity; 4. In addition to emergency medications, the emergency medication cart should also provide standardized guidelines for the use of emergency medications with the same dosage, form, and concentration as the medications provided; 5. Before injecting contrast agents, use standardized protocols to assess the risk of allergic reactions and kidney damage in patients. Reduce the probability of these risks by avoiding contraindicated drugs, selecting non-ionic contrast agents, or using hydration, extending the administration time, etc.; 6. Establish a standardized medication administration time management process within the hospital to help nurses execute medication orders at the correct time (such as the specific time point for executing long-term medication orders daily, how to select subsequent administration times if the first administration is at a non-standard time, etc.).

[0076] Regarding pharmaceutical management, potential risks include: 1. Clearly defining the list of high-alert drugs used within the institution, establishing management procedures to reduce medication errors related to high-alert drugs, and providing hospital-wide training to physicians, pharmacists, and nurses to ensure that all relevant medical staff are aware of the high-alert drug list and management procedures; 2. Establishing standardized intravenous rehydration protocols for pediatric patients after surgery, and using these protocols to identify, treat, and monitor potential hyponatremia, water intoxication, and syndrome of indigestion (SIADH); 3. Medical institutions should organize pharmacists and other professional technicians to analyze and summarize internal reports and literature reports on medication errors and adverse drug events related to drugs listed in the drug list, and take necessary measures to reduce drug risks. 4. When necessary, remove high-risk drugs from the institution's drug catalog; 5. The Hospital Pharmacy Management and Therapeutics Committee, based on evidence-based medicine, establishes clinical pathways and formulates standardized and procedural treatment plans with strict work sequences and accurate time requirements to standardize medical practices, ensure patient safety, and enable patients to receive appropriate medical and nursing services; 6. To ensure that medication orders are executed within a reasonable time, wards store a certain number of drugs based on their intended use (e.g., specially managed anesthetics and ward-specific drugs) by establishing basic drug cabinets, emergency drug carts, or using smart drug cabinets; 7. The hospital establishes effective contingency plans to address situations such as staff shortages due to sick leave, vacations, or off-site training, or fluctuations in workload due to a sudden increase in patients.

[0077] After identifying drug management risk points, it is necessary to determine the risk indicators for these risk points. In this embodiment, the risk indicators include a first indicator, a second indicator, and a third indicator. Specifically, risk severity, risk occurrence probability, and risk controllability are selected as the first, second, and third indicators, respectively. In other embodiments, other risk indicators, such as risk duration, can also be selected. This embodiment only uses three risk indicators as an example for illustration and does not impose any limitations on them.

[0078] Step S102: For each drug management risk point, the risk indicators are divided into multiple levels and quantitatively scored. Each level corresponds to a different degree and a different score. The risk indicators are assigned scores based on their levels.

[0079] In this embodiment, the severity of drug risk is divided into five levels: catastrophic (5 points), severe (4 points), moderate (3 points), minor (2 points), and negligible (1 point).

[0080] The probability of drug risk is divided into five levels: almost inevitable (5 points), repeated (4 points), rare (3 points), occasional (2 points), and almost never (1 point).

[0081] The controllability of drug risks is divided into five levels: almost uncontrollable (5 points), difficult to control (4 points), controllable (3 points), easy to control (2 points), and negligible (1 point).

[0082] In other embodiments, the risk indicators may be divided into other numbers of levels and assigned corresponding scores.

[0083] Each time an updated drug management risk point is obtained, a score for each risk indicator is directly assigned to each drug management risk point. This can be done through methods such as expert evaluation and process evaluation. For example, by setting drug management standards, scoring tasks can be assigned to each drug management process. In daily management, staff at each drug management process can score the risk indicators of the drug management risk points and summarize them regularly to obtain the score for each risk indicator.

[0084] For example, for drug management risk point A, the indicator scores could be 4 points for the risk severity indicator, 2 points for the risk probability indicator, and 4 points for the risk controllability indicator.

[0085] Furthermore, a drug risk matrix is ​​constructed for multiple risk indicators. In this embodiment, to facilitate the differentiation of different risk regions, two indicators are arbitrarily selected from multiple risk indicators to construct a drug risk matrix, thereby obtaining multiple drug risk matrices for different risk indicators. For example, for the three risk indicators mentioned above, a first drug risk matrix is ​​first established based on risk severity (first indicator) and risk occurrence probability (second indicator); then a second drug risk matrix is ​​established based on risk severity (first indicator) and risk controllability (third indicator); finally, a third drug risk matrix is ​​established based on risk occurrence probability (second indicator) and risk controllability (third indicator).

[0086] After establishing the drug risk matrix, according to the ALARP principle, the first drug risk matrix, the second drug risk matrix, and the third drug risk matrix are divided into risk areas. In this embodiment, the risk matrix includes high-risk areas, medium-risk areas, and low-risk areas. It can be seen that each risk area corresponds to a combination of the index scores of two risk indicators corresponding to the risk matrix.

[0087] The ALARP principle divides risk into three zones using two risk demarcation lines: the unacceptable zone, the tolerable zone (ALARP zone), and the broadly acceptable zone, referred to in this embodiment as the high-risk zone, medium-risk zone, and low-risk zone, respectively. The ALARP principle emphasizes reasonable feasibility and maximizing risk reduction, requiring decision-makers to take any reasonable safety measures to minimize risk.

[0088] In this embodiment, for any two risk indicators, the drug risk matrix is ​​divided into different risk regions according to the ALARP principle, as shown in Tables 1, 2, and 3:

[0089] Table 1 shows the risk matrix for first-line drugs based on risk severity and probability of occurrence, along with corresponding risk areas.

[0090]

[0091] Table 2 shows the risk matrix for second-party drugs and the corresponding risk areas based on risk severity and risk controllability.

[0092]

[0093] Table 3 shows the third-party drug risk matrix and corresponding risk areas based on the probability of risk occurrence and the controllability of risk.

[0094]

[0095] For example, regarding the severity and probability of risk occurrence, if a drug management risk point has a severity score of 4 (severe) and a probability of occurrence score of 3 (possible), then the risk area where the drug management risk point is located is a high-risk area.

[0096] Specifically, refer to Figure 2 The method for determining the risk area in this embodiment includes:

[0097] S201. Based on the ALARP principle, the first drug risk matrix, the second drug risk matrix, and the third drug risk matrix are divided into risk areas, including high-risk areas, medium-risk areas, and low-risk areas.

[0098] S202. Obtain the first high-risk area in the first drug risk matrix, the second high-risk area in the second drug risk matrix, and the third high-risk area in the third drug risk matrix. Merge the first high-risk area, the second high-risk area, and the third high-risk area to obtain the merged high-risk area.

[0099] S203. Obtain the first medium-risk area in the first drug risk matrix, the second medium-risk area in the second drug risk matrix, and the third medium-risk area in the third drug risk matrix. Merge the first medium-risk area, the second medium-risk area, and the third medium-risk area to obtain the merged medium-risk area.

[0100] S204. Obtain the first low-risk area in the first drug risk matrix, the second low-risk area in the second drug risk matrix, and the third low-risk area in the third drug risk matrix. Merge the first low-risk area, the second low-risk area, and the third low-risk area to obtain the merged low-risk area.

[0101] In this embodiment, the low-risk, medium-risk, and high-risk areas in the three risk matrices are merged according to region type to obtain low-risk, medium-risk, and high-risk areas for the three risk indicators, and the corresponding indicator scores of the low-risk, medium-risk, and high-risk areas are stored.

[0102] Based on a drug risk matrix constructed from any two risk indicators, the risk indicators are divided into risk regions according to their scores. Then, the same risk regions in all drug risk matrices are merged to obtain various risk regions in multiple risk matrices. Compared with directly constructing a multidimensional risk matrix from three or more risk indicators, dividing risk regions from the multidimensional risk matrix can greatly improve the accuracy of risk region division, thereby reducing the possibility of serious consequences due to inaccurate risk region division.

[0103] For example, the first high-risk area in the first drug risk matrix, the second high-risk area in the second drug risk matrix, and the third high-risk area in the third drug risk matrix are obtained. These three high-risk areas are then merged to obtain high-risk areas for the three risk indicators. The corresponding indicator scores within each high-risk area are then merged to obtain all possible combinations of indicator scores for all high-risk areas. If the indicator score for a drug management risk point falls within a combination of indicator scores for a high-risk area, then that drug management risk point is identified as a high-risk drug management point.

[0104] It is worth noting that if a set of indicator scores results in different risk area classifications in different drug risk matrices, the risk area classification is based on the highest risk area level among the various indicator scores. For example, an indicator score of (1, 5, 5) indicates a risk severity score of 1, a risk occurrence probability score of 5, and a risk controllability score of 5. In the drug risk matrix corresponding to risk severity and risk occurrence probability in Table 1 above, this indicator score should be classified as a medium-risk area. However, in the drug risk matrix corresponding to risk occurrence probability and risk controllability in Table 3 above, this indicator score should be classified as a high-risk area. In this case, the indicator score is classified as the higher-level risk area between the medium-risk and high-risk areas, i.e., the high-risk area.

[0105] As shown in Table 4, examples of indicator score combinations for some low-risk, medium-risk, and high-risk areas in this embodiment are given:

[0106] Table 4 shows examples of indicator score combinations for low-risk, medium-risk, and high-risk areas.

[0107]

[0108]

[0109] After obtaining the indicator score combinations for high-risk areas, all indicator score combinations corresponding to high-risk areas are stored in the database to facilitate the regional division of new drug bottle management risk points. Furthermore, since there may be duplicate indicator scores within the first, second, and third high-risk areas, the indicator score combinations for high-risk areas can be deduplicated to save storage space.

[0110] Step S103: The above steps of dividing risk areas through the drug risk matrix are the preliminary steps of this embodiment. After obtaining the updated drug management risk points and corresponding indicator scores, the indicators of the drug management risk points are matched in the corresponding combinations of low-risk, medium-risk, and high-risk areas to determine the risk area where the indicator score of the current drug management risk point is located.

[0111] For example, if a newly acquired drug management risk point has an index score of (2, 4, 1) for the three risk indicators, it means that the risk severity score is 2 points, the risk occurrence probability score is 4 points, and the risk controllability score is 1 point. Since the index score is in the high-risk zone, the drug management risk point is determined to be a high-risk drug management point.

[0112] Step S104: In this embodiment, the first rectification sequence for drug management risk points is determined by calculating the risk score of each risk point. Calculating the risk score requires determining the weights of multiple risk indicators, and then weighted summing the scores of each risk indicator to obtain the risk score for the high-risk drug management point.

[0113] In one embodiment of this example, the weights of risk indicators for drug management risk points can be calculated using the Analytic Hierarchy Process (AHP). (Refer to...) Figure 3 In this embodiment, the method for obtaining the indicator weights of the risk indicators includes:

[0114] S301. Construct a hierarchical model. The hierarchical model includes an objective layer and a criterion layer. The objective layer is used to calculate the weights of the indicators, and the criterion layer includes risk indicators.

[0115] S302. Construct a judgment matrix based on the risk indicators in the criteria layer;

[0116] S303. Obtain the largest eigenvalue of the judgment matrix and the largest eigenvector corresponding to the largest eigenvalue;

[0117] S304. Determine the weight of each risk indicator based on the largest eigenvector.

[0118] First, a hierarchical model is established, which includes an objective layer and a criterion layer. The objective layer represents the weights of the indicators that need to be calculated, while the criterion layer covers all risk indicators, such as the aforementioned risk severity, probability of risk occurrence, and controllability of risk.

[0119] A judgment matrix H is constructed based on the risk indicators in the criterion layer. This judgment matrix represents a comparison of the relative importance of all risk indicators in the criterion layer with respect to the target layer, thereby determining the proportion of each risk indicator in the drug management risk points. All risk indicators are compared pairwise to form an n*n judgment matrix H (where n is the number of risk indicators, which can be 3 in this embodiment):

[0120]

[0121] In this embodiment, x and y can be any numbers from 1, 2, and 3. Where h... xy Comparing two risk indicators, x and y, the importance of risk indicator x relative to risk indicator y is, for example, in the above embodiment, h 12 This indicates the importance of risk severity relative to the probability of risk occurrence. Based on Saaty's 1-9 scale, numerical values ​​ranging from 1 to 9 are given, where h... xy >0, h xy =1 / h yx (x≠y), h xx =1.

[0122] The 1-9 scale is a scaling method used in the Analytic Hierarchy Process (AHP) to determine the relative importance of factors. This method divides the importance of comparisons into nine levels, from 1 to 9, with higher numbers indicating greater importance of one factor relative to another.

[0123] The specific scaling description is as follows:

[0124] 1: The two factors are equally important.

[0125] 2: One factor is slightly more important than the other.

[0126] 3: One factor is clearly more important than the other.

[0127] 4: One factor is significantly more important than the other.

[0128] 5: One factor is stronger than the other.

[0129] 6: One factor is significantly more important than the other.

[0130] 7: One factor is far more important than the other.

[0131] 8: One factor is significantly more important than the other.

[0132] 9: One factor is far more important than the other.

[0133] When using the 1-9 scale for pairwise comparisons, each factor needs to be compared with each other one by one, and then a scale value is assigned according to its relative importance. In this embodiment, scaling two indicators can be done through expert scoring and group discussion.

[0134] Furthermore, after constructing the judgment matrix, the weight of each risk indicator can be calculated based on the judgment matrix. In this embodiment, the indicator weight is determined by calculating the largest eigenvalue and the corresponding largest eigenvector in the judgment matrix.

[0135] Specifically, the numpy.linalg.eig function in the numpy library can be used to calculate the maximum eigenvalue and maximum eigenvector of the judgment matrix. Of course, it can also be calculated manually, but for larger matrices, the manual calculation process is cumbersome. Therefore, this embodiment uses a computer programming language to assist in the calculation, so as to improve the calculation efficiency and make it easier to adapt to the actual situation of different risk indicators.

[0136] After obtaining the largest eigenvector of the judgment matrix, the relative importance of each risk indicator can be determined. The largest eigenvector is then normalized so that the sum of its elements is 1. The normalized vector is then the indicator weight of each risk indicator.

[0137] Furthermore, after constructing the judgment matrix, a consistency check needs to be performed on the judgment matrix to ensure that the judgment matrix is ​​reasonable and consistent. In this embodiment, this is accomplished by calculating the consistency ratio CR of the judgment matrix. If CR is less than 0.1, the judgment matrix is ​​considered to be consistent.

[0138] Specifically, the consistency ratio (CR) is calculated using the formula: CR = CI / RI, where CI is the consistency index and RI is the random consistency index. The consistency index CI is calculated as: CI = (λmax - n) / (n - 1), where λmax is the largest eigenvalue of the judgment matrix and n is the order of the judgment matrix. RI is the random consistency index, and it has a fixed value for different values ​​of n. In practical applications, the corresponding RI value can be directly looked up. After obtaining CI and RI, substituting them into the CR calculation formula yields the consistency ratio (CR). When CR is less than 0.1, the consistency of the judgment matrix is ​​generally considered acceptable; otherwise, the judgment matrix needs to be corrected.

[0139] After determining the weight of each risk indicator, the risk score of the drug management risk point is calculated by weighting and summing the indicator scores based on the indicator weights and the indicator scores of each risk indicator of the drug management risk point.

[0140] For example, the risk indicators for risk severity, risk probability, and risk controllability have corresponding weights of 0.4, 0.3, and 0.3, respectively. If the indicator score for a certain drug management risk point is (2, 4, 1), then the risk score for that drug management risk point is calculated as: 2*0.4 + 4*0.3 + 1*0.3 = 2.3.

[0141] Step S105: As mentioned above, if the indicator score of a drug management risk point is in the high-risk zone, then the drug management risk point is determined to be a high-risk drug management point; if the indicator score of a drug management risk point is in the medium-risk zone, then the drug management risk point is determined to be a medium-risk drug management point; if the indicator score of a drug management risk point is in the low-risk zone, then the drug management risk point is determined to be a low-risk drug management point.

[0142] After obtaining the risk scores of all current drug management risk points, the risk points can be arranged in descending order of risk score to obtain the first rectification sequence of drug management risk points.

[0143] Specifically, for all drug management risk points, the rectification order will be determined by ranking them separately according to different risk areas. High-risk drug management points will be ranked by risk score to obtain a high-risk rectification sequence; medium-risk drug management points will be ranked by risk score to obtain a medium-risk rectification sequence; and low-risk drug management points will be ranked by risk score to obtain a low-risk rectification sequence.

[0144] More specifically, in the first rectification sequence, the high-risk rectification sequence as a whole precedes the medium-risk rectification sequence, and the medium-risk rectification sequence as a whole precedes the low-risk rectification sequence. The higher a point ranks in the rectification sequence, the higher its level of rectification needs and the more urgent it is to rectify.

[0145] It is worth mentioning that during the rectification process, the high-risk points in drug management in the high-risk point rectification sequence should be rectified first in the order of the first rectification sequence. The subsequent medium-risk points and low-risk points in drug management can be assessed for risk and cost-effectiveness based on the actual situation to determine whether to take further risk control measures to ensure that the risks remain within a controllable range.

[0146] At this point, this embodiment has completed the risk area division, risk score calculation, and acquisition of the first rectification sequence for all drug management risk points in the current batch. Through the design of this embodiment, the urgency of rectification for drug management risk points can be automatically ranked, facilitating the identification and improvement of risks in the drug management process.

[0147] In another embodiment of this example, after obtaining the risk scores of all drug management risk points, especially the high-risk point sequence of high-risk drug management points, there may be cases where two or more drug management risk points have the same risk score. In this case, it is necessary to further sort the identical drug management risk points using the Borda ordinal method. (Refer to...) Figure 4 Specifically, it includes:

[0148] S401. In response to the fact that any two or more drug management risk points have the same risk score, calculate the Borda number of drug management risk points with the same risk score based on the Borda ordinal value method.

[0149] S402. Based on the Borda number, drug management risk points with the same risk score are ranked to obtain the second rectification sequence of drug management risk points;

[0150] S403. Based on the first rectification sequence and the second rectification sequence, determine the target rectification sequence for drug management risk points.

[0151] Borda ordinal ranking is a method based on ranking alternatives. It assigns different scores (typically (n-1), (n-2), to 0) to the 1st, 2nd, and nth ranked alternatives according to each decision-maker's ranking of the alternative set. This method can perform cross-category risk assessment in a risk matrix.

[0152] Specifically, the Borda ordinal ranking method ranks risks by calculating their Borda number; a higher Borda number indicates a higher risk level. The formula for calculating the Borda number is as follows:

[0153]

[0154] Where n is the number of risk indicators, N is the total number of drug management risk points, and Rank i It is the ranking of the risk point on the i-th risk indicator, ω i This is the indicator weight of the i-th risk indicator. After calculating the Borda number of all drug management risk points, the Borda numbers are summarized and sorted according to their magnitude. The higher the Borda number, the higher the overall risk of the drug management risk point.

[0155] For example, suppose there are three high-risk drug management points (A, B, C) with the same risk score. The risk indicators are set as three: severity, probability of occurrence, and controllability. The weights of the corresponding risk indicators are 0.4, 0.3, and 0.3, respectively, and the ranking of the risk points on each indicator is shown in Table 5.

[0156] Table 5. Ranking of High-Risk Points A, B, and C in Drug Management on Each Risk Indicator

[0157]

[0158]

[0159] Therefore, the Borda number for each drug management risk point is calculated as follows:

[0160] Regarding drug management risk point A:

[0161] BordaScore=(3-1)*0.4+(3-2)*0.3+(3-3)*0.3=1.1;

[0162] Regarding drug management risk point B:

[0163] BordaScore=(3-2)*0.4+(3-1)*0.3+(3-2)*0.3=1.3;

[0164] Regarding drug management risk point C:

[0165] BordaScore=(3-3)*0.4+(3-3)*0.3 / 3+(3-1)*0.3=0.6;

[0166] As can be seen from the above example, the Borda number of high-risk point B in drug management is the largest, so the overall risk of high-risk point B in drug management is the highest, followed by high-risk point A in drug management, and lastly high-risk point C in drug management.

[0167] Based on the Borda numbers of multiple drug management risk points with the same risk score, their second rectification sequence is determined. As shown by the distance above, the second rectification sequence is: Drug Management High-Risk Point B > Drug Management High-Risk Point A > Drug Management High-Risk Point C.

[0168] By combining the second rectification sequence and the first rectification sequence, the target rectification sequence for all drug management risk points can be obtained, so that medical institutions can rectify drug management risk points according to the target rectification sequence.

[0169] To achieve the above embodiments, this application also proposes a drug management risk assessment device.

[0170] Reference Figure 5 The device includes:

[0171] Basic data acquisition module 1 is used to acquire drug management risk points and risk indicators of drug management risk points;

[0172] Indicator score calculation module 2 is used to obtain the indicator score for each risk indicator of drug management risk points;

[0173] Risk area classification module 3 is used to determine the risk area where the indicator score is located from the preset drug risk matrix based on the indicator score;

[0174] Risk score calculation module 4 is used to calculate the risk score of drug management risk points based on the indicator weights and indicator scores of risk indicators.

[0175] The rectification sequence acquisition module 5 is used to sort all drug management risk points based on risk areas and risk scores, and obtain the first rectification sequence of drug management risk points.

[0176] Furthermore, in one possible implementation of this application embodiment, the rectification sequence acquisition module 5 is also used to calculate the Borda number of drug management risk points with the same risk score based on the Borda ordinal value method in response to any two or more drug management risk points having the same risk score.

[0177] The rectification sequence acquisition module 5 is also used to sort drug management risk points with the same risk score based on the Borda number and obtain the second rectification sequence of drug management risk points;

[0178] The rectification sequence acquisition module 5 is also used to determine the target rectification sequence of drug management risk points based on the first rectification sequence and the second rectification sequence.

[0179] It should be noted that the foregoing explanation of an embodiment of a drug management risk assessment method also applies to a drug management risk assessment device of the same embodiment, and will not be repeated here.

[0180] To implement the above embodiments, this application also proposes an electronic device, including: a processor and a memory communicatively connected to the processor; the memory stores computer execution instructions; the processor executes the computer execution instructions stored in the memory to implement the method provided in the foregoing embodiments.

[0181] To implement the above embodiments, this application also proposes a computer-readable storage medium storing computer-executable instructions, which, when executed by a processor, are used to implement the methods provided in the foregoing embodiments.

[0182] The collection, storage, use, processing, transmission, provision, and disclosure of user personal information involved in this application all comply with the provisions of relevant laws and regulations and do not violate public order and good morals.

[0183] It should be noted that personal information collected from users should be used for legitimate and reasonable purposes and should not be shared or sold outside of these legitimate uses. Furthermore, such collection / sharing should only be conducted after receiving the user's informed consent, including but not limited to notifying the user to read the user agreement / user notice and sign an agreement / authorization that includes authorization of relevant user information before the user uses the function. In addition, any necessary steps must be taken to protect and safeguard access to such personal information data and ensure that others with access to personal information data comply with their privacy policies and procedures.

[0184] This application is intended to provide an implementation scheme for users to selectively prevent the use or access to their personal information data. Specifically, this disclosure is intended to provide hardware and / or software to prevent or block access to such personal information data. Once personal information data is no longer needed, risks can be minimized by restricting data collection and deleting data. Furthermore, where applicable, such personal information is de-identified to protect user privacy.

[0185] In the foregoing descriptions of the embodiments, the terms "one embodiment," "some embodiments," "example," "specific example," or "some examples," etc., refer to specific features, structures, materials, or characteristics described in connection with that embodiment or example, which are included in at least one embodiment or example of this application. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples. Moreover, without contradiction, those skilled in the art can combine and integrate the different embodiments or examples described in this specification, as well as the features of different embodiments or examples.

[0186] Furthermore, the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include at least one of that feature. In the description of this application, "multiple" means at least two, such as two, three, etc., unless otherwise explicitly specified.

[0187] Any process or method description in the flowchart or otherwise herein can be understood as representing a module, segment, or portion of code comprising one or more executable instructions for implementing custom logic functions or processes, and the scope of the preferred embodiments of this application includes additional implementations in which functions may be performed not in the order shown or discussed, including substantially simultaneously or in reverse order depending on the functions involved, as should be understood by those skilled in the art to which embodiments of this application pertain.

[0188] The logic and / or steps represented in the flowchart or otherwise described herein, for example, can be considered as a sequenced list of executable instructions for implementing logical functions, and can be embodied in any computer-readable medium for use by, or in conjunction with, an instruction execution system, apparatus, or device (such as a computer-based system, a processor-included system, or other system that can fetch and execute instructions from, an instruction execution system, apparatus, or device). For the purposes of this specification, "computer-readable medium" can be any means that can contain, store, communicate, propagate, or transmit programs for use by, or in conjunction with, an instruction execution system, apparatus, or device. More specific examples (a non-exhaustive list) of computer-readable media include: an electrical connection having one or more wires (electronic device), a portable computer disk drive (magnetic device), random access memory (RAM), read-only memory (ROM), erasable and editable read-only memory (EPROM or flash memory), fiber optic devices, and portable optical disc read-only memory (CDROM). Alternatively, the computer-readable medium may be paper or other suitable media on which the program can be printed, since the program can be obtained electronically, for example, by optically scanning the paper or other medium, followed by editing, interpreting, or otherwise processing as necessary, and then stored in a computer memory.

[0189] It should be understood that various parts of this application can be implemented using hardware, software, firmware, or a combination thereof. In the above embodiments, multiple steps or methods can be implemented using software or firmware stored in memory and executed by a suitable instruction execution system. For example, if implemented in hardware as in another embodiment, it can be implemented using any one or a combination of the following techniques known in the art: discrete logic circuits having logic gates for implementing logical functions on data signals, application-specific integrated circuits (ASICs) having suitable combinational logic gates, programmable gate arrays (PGAs), field-programmable gate arrays (FPGAs), etc.

[0190] Those skilled in the art will understand that all or part of the steps of the methods in the above embodiments can be implemented by a program instructing related hardware. The program can be stored in a computer-readable storage medium, and when executed, the program includes one or a combination of the steps of the method embodiments.

[0191] Furthermore, the functional units in the various embodiments of this application can be integrated into a processing module, or each unit can exist physically separately, or two or more units can be integrated into a module. The integrated module can be implemented in hardware or as a software functional module. If the integrated module is implemented as a software functional module and sold or used as an independent product, it can also be stored in a computer-readable storage medium.

[0192] The storage medium mentioned above can be a read-only memory, a disk, or an optical disk, etc. Although embodiments of this application have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting this application. Those skilled in the art can make changes, modifications, substitutions, and variations to the above embodiments within the scope of this application.

Claims

1. A method for assessing drug management risks, characterized in that, include: Obtain the updated drug management risk points and the risk indicators of the drug management risk points; Obtain the indicator score for each of the aforementioned drug management risk indicators; Based on the index score, the risk zone in which the index score is located is determined from the preset drug risk matrix; The risk score of the drug management risk point is calculated based on the indicator weight and the indicator score of the risk indicator. Based on the risk areas and risk scores, all drug management risk points are sorted to obtain the first rectification sequence of drug management risk points.

2. The method according to claim 1, characterized in that, In response to the risk indicators including a first indicator, a second indicator, and a third indicator, the method for constructing the drug risk matrix includes: A first drug risk matrix is ​​constructed based on the first indicator, the score of the first indicator, the second indicator, and the score of the second indicator; A second drug risk matrix is ​​constructed based on the first indicator, the score of the first indicator, the third indicator, and the score of the third indicator; A third drug risk matrix is ​​constructed based on the second indicator, the score of the second indicator, the third indicator, and the score of the third indicator.

3. The method according to claim 2, characterized in that, The method for determining the risk area includes: Based on the ALARP principle, the first drug risk matrix, the second drug risk matrix and the third drug risk matrix are divided into risk regions, which include high-risk areas, medium-risk areas and low-risk areas. Obtain the first high-risk area in the first drug risk matrix, the second high-risk area in the second drug risk matrix, and the third high-risk area in the third drug risk matrix. Then merge the first high-risk area, the second high-risk area, and the third high-risk area to obtain the merged high-risk area. Obtain the first medium-risk area in the first drug risk matrix, the second medium-risk area in the second drug risk matrix, and the third medium-risk area in the third drug risk matrix. Then merge the first medium-risk area, the second medium-risk area, and the third medium-risk area to obtain the merged medium-risk area. Obtain the first low-risk area in the first drug risk matrix, the second low-risk area in the second drug risk matrix, and the third low-risk area in the third drug risk matrix. Then merge the first low-risk area, the second low-risk area, and the third low-risk area to obtain the merged low-risk area.

4. The method according to claim 1, characterized in that, The method for obtaining the indicator weights of the risk indicators includes: A hierarchical model is constructed, which includes an objective layer and a criterion layer. The objective layer is used to calculate the weights of the indicators, and the criterion layer includes the risk indicators. Based on the risk indicators in the criterion layer, a judgment matrix is ​​constructed; Obtain the maximum eigenvalue of the judgment matrix and the maximum eigenvector corresponding to the maximum eigenvalue; The weight of each risk indicator is determined based on the maximum eigenvector.

5. The method according to claim 1, characterized in that, After calculating the risk score of the high-risk point in drug management based on the indicator weights and scores of the risk indicators, the method further includes: In response to the fact that any two or more of the drug management risk points have the same risk score, the Borda number of the drug management risk points with the same risk score is calculated based on the Borda ordinal value method. Based on the Borda number, the drug management risk points with the same risk score are ranked to obtain the second rectification sequence of the drug management risk points; Based on the first rectification sequence and the second rectification sequence, the target rectification sequence for the drug management risk points is determined.

6. The method according to claim 1, characterized in that, The method for obtaining the drug management risk points includes: Obtain historical medication error cases and identify initial drug management risk points from these cases; The initial drug management risk points are preprocessed to determine the drug management risk points.

7. A drug management risk assessment device, characterized in that, include: The basic data acquisition module is used to acquire drug management risk points and risk indicators of the drug management risk points; The indicator score calculation module is used to obtain the indicator score of each of the drug management risk points for each risk indicator; The risk area division module is used to determine the risk area where the indicator score is located from a preset drug risk matrix based on the indicator score. The risk score calculation module is used to calculate the risk score of the drug management risk point based on the indicator weight and the indicator score of the risk indicator. The rectification sequence acquisition module is used to sort all the drug management risk points based on the risk area and the risk score, and obtain the first rectification sequence of the drug management risk points.

8. The apparatus according to claim 7, characterized in that, The rectification sequence acquisition module is also used to calculate the Borda number of drug management risk points with the same risk score based on the Borda ordinal value method in response to any two or more drug management risk points having the same risk score. The rectification sequence acquisition module is also used to sort the drug management risk points with the same risk score based on the Borda number, and obtain the second rectification sequence of the drug management risk points. The rectification sequence acquisition module is also used to determine the target rectification sequence of the drug management risk point based on the first rectification sequence and the second rectification sequence.

9. An electronic device, characterized in that, include: A processor, and a memory communicatively connected to the processor; The memory stores computer-executed instructions; The processor executes computer execution instructions stored in the memory to implement the method as described in any one of claims 1-6.

10. A computer-readable storage medium, characterized in that, The computer-readable storage medium stores computer-executable instructions, which, when executed by a processor, are used to implement the method as described in any one of claims 1-6.

Images